about
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a reviewCO2 laser therapy of the Bartholin's gland cyst: surgical data and functional short- and long-term results.Chemotherapy in elderly patients with gynecological cancer.Recurrent Buschke-Löwenstein tumor treated using CO(2) laser vaporization.CO2 laser treatment for Bartholin gland abscess: ultrasound evaluation of risk recurrence.Aortic lymphadenectomy in cervical cancer: anatomy, classification and technique.Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials.Urethral coitus in a patient with a microperforate hymen.Splenic metastasis from cervical cancer: case report and review of the literature.Hormone therapy in oophorectomized BRCA1/2 mutation carriers.Surgical treatment of an isolated omental cervical cancer recurrence: report of a case and review of the literature.Emergency peripartum hysterectomy in a tertiary teaching hospital: a 14-year review.Surgical Treatment of Recurrent Endometrial Cancer: Time for a Paradigm Shift.Prognostic role of inguinal lymphadenectomy in vulvar squamous carcinoma: younger and older patients should be equally treated. A prospective study and literature review.Continuous versus cyclic oral contraceptives after laparoscopic excision of ovarian endometriomas: a systematic review and metaanalysis.Surgical Techniques for Diaphragmatic Resection During Cytoreduction in Advanced or Recurrent Ovarian Carcinoma: A Systematic Review and Meta-analysis.Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies.Ixabepilone for the treatment of endometrial cancer.Impact of Surgical Route in Influencing the Risk of Lymphatic Complications After Ovarian Cancer Staging.Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions.Trends in Mortality After Primary Cytoreductive Surgery for Ovarian Cancer: A Systematic Review and Metaregression of Randomized Clinical Trials and Observational Studies.Surgical Management and Prognostic Factors of Vulvovaginal Melanoma.Antibiotics Prophylaxis for Operative Hysteroscopy.Type B versus Type C Radical Hysterectomy After Neoadjuvant Chemotherapy in Locally Advanced Cervical Carcinoma: A Propensity-Matched Analysis.Fertility-sparing surgery in early-stage cervical cancer patients: oncologic and reproductive outcomes.Laparoscopically guided minilaparotomy: a minimally invasive approach for the treatment of gynaecologic diseases in morbidly obese patients.Vaginectomy: a minimally invasive treatment for cervical cancer vaginal recurrence.Recto-vaginal septum hematoma: conservative management of a rare complication after radical hysterectomy.Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma.Is postoperative computed tomography evaluation a prognostic indicator in patients with optimally debulked advanced ovarian cancer?Severe pelvic organ prolapse treated by vaginal native tissue repair: long-term analysis of outcomes in 146 patients.Vulvo-vaginal reconstruction after radical excision for treatment of vulvar cancer: Evaluation of feasibility and morbidity of different surgical techniques.Sexual Health and Quality of Life Assessment among Ovarian Cancer Patients during Chemotherapy.Quality of life and sexual function after type C2/type III radical hysterectomy for locally advanced cervical cancer: a prospective study.Effects of Neoadjuvant Chemotherapy Plus Radical Surgery as Front Line Treatment Strategy in Patients Affected by FIGO Stage III Cervical Cancer.Dose-Dense Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced Cervical Cancer: A Phase II Study.Impact of Hormone Receptor Status and Ki-67 Expression on Disease-Free Survival in Patients Affected by High-risk Endometrial Cancer.Bartholin gland cancer.Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study.Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms.
P50
Q26828581-721EFCAF-D73B-486F-92A9-92A0DDC55E8DQ31111545-7B7CA0AF-7C53-457C-A77E-AA06BE43D28EQ33410185-2A6B83C5-1892-473E-ABF5-EB8046486703Q33668221-364F0B63-B13A-4E3F-BD04-DDFFE4163927Q34574086-2583B80F-33AB-4870-B080-51DA4D828994Q36922658-C9FEB1DB-43E7-499B-86BF-739D325E66E2Q37022434-D27AC562-72BA-4D5A-B395-D4F9425D8E47Q37250568-DA65EB67-D463-41FB-85DF-DE4170A1D166Q37778332-E879F78E-12D9-44B5-9B28-0C98A8864F0FQ38164226-79CA184A-F612-4724-9CAE-08D48A29A2EAQ38213889-A04F5C28-8927-4579-948B-5E649628F35EQ38254075-23DFC750-2D13-477B-8B6D-244AA59B35CCQ38380255-DA77A218-D76F-440A-BCF5-899D783C9EB1Q38426654-24F23A7D-0187-4DC3-B091-00F977D24F3DQ38585908-8336EC39-5B51-4EC4-9D6E-1E0CD31BF039Q38640230-C516A4C5-0623-47BB-9924-E1148C873964Q38682200-4DD6A67B-A17C-421F-BE00-830165765BBCQ38763500-F290A482-8151-471D-97C7-F222A2896B56Q38872984-2BDFCAE6-0EF5-4AFE-8BB1-4ADA025491F9Q38994357-45EBDF64-753B-4FE8-BAEA-A9EF6421A44AQ39023165-D116C844-8A51-4C5C-975B-96A7D152B6ADQ39875767-BDFC68D6-3623-47A2-9CE3-F189060997C5Q40094876-E329F092-DAA4-4772-9443-6723677D7542Q40285797-6D5DBAA7-B7B4-4A5D-BEA7-9E7776391D37Q41516707-8F414321-F87B-48CF-B972-A01D762C581FQ43641157-BC2EF6CE-F6BA-4416-BA5B-5A601C20D3D9Q43800896-9D12BE39-2A12-470D-BC17-7EE8542455C1Q43835328-5563B3EC-B211-45F6-AEA5-4AE8CA033DC9Q44247526-882E1713-6228-414A-A46E-1A301C0E101DQ44296212-E4B339FA-BAD5-48FF-BF3A-EB6FAF4E6000Q47573899-9C08D7E9-AC20-453F-94EE-E5ABF742E881Q47587112-E59CFFEC-AEDE-4CE0-BD40-22DE99F2AD9DQ47678068-12286E19-43C5-442E-93BD-DD5E31178970Q48732404-0F7EDB4A-814E-474E-A688-A3C51E2DF986Q49023663-CF59D948-BCB1-4E1C-B4FF-BD555819DF9BQ49086612-1AF713EF-56E4-46AB-9EA3-96C8E0B9B38EQ49712610-AFF3BEF2-D776-4031-BF6D-3EC375F08CF1Q51807994-8DA7D866-45FF-4C1B-A10E-EDA5E77FF424Q51825430-EF0389A1-77A4-48D5-BB1F-E3E973A4C0ABQ53496298-297DA4BF-0094-4253-BC5F-0F32267DDC54
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Violante Di Donato
@ast
Violante Di Donato
@en
Violante Di Donato
@es
Violante Di Donato
@sl
type
label
Violante Di Donato
@ast
Violante Di Donato
@en
Violante Di Donato
@es
Violante Di Donato
@sl
altLabel
donato vd
@en
prefLabel
Violante Di Donato
@ast
Violante Di Donato
@en
Violante Di Donato
@es
Violante Di Donato
@sl
P1053
J-1556-2012
P106
P1153
15080693600
P21
P31
P3829
P496
0000-0002-9254-5790